What is the recommended management for a pregnancy complicated by fetal cystic hygroma, including diagnostic evaluation, monitoring, and potential fetal or perinatal interventions?

Management of Pregnancy with Cystic Hygroma

Pregnancies complicated by fetal cystic hygroma require immediate comprehensive genetic evaluation with karyotype analysis or chromosomal microarray, detailed anatomic ultrasound screening for structural anomalies, and serial surveillance with counseling tailored to the presence or absence of aneuploidy, structural defects, and hydrops fetalis.

Initial Diagnostic Evaluation

When cystic hygroma is identified prenatally, the following workup is essential:

Genetic Testing

• Offer invasive diagnostic testing immediately - chromosomal abnormalities occur in approximately 55% of cases 1
• The most common aneuploidies are:
  • Turner syndrome (21%)
  • Trisomy 21 (17%)
  • Trisomy 18 (10%)
  • Trisomy 13 (3%)
  • Other genetic diagnoses (5%) 1
• Chromosomal microarray analysis is preferred over standard karyotype, as it can detect non-aneuploidy genetic diagnoses that occur in a significant proportion of cases 1
• For first-trimester detection with nuchal translucency ≥3mm, approximately one-third will have chromosomal abnormalities 2

Structural Anomaly Screening

• Perform detailed anatomic ultrasound - major structural anomalies are present in 42% of all cases 1
• Importantly, 16% of fetuses with cystic hygroma and structural abnormalities have normal karyotypes 1
• Fetal echocardiography is mandatory - cardiac malformations are particularly common and have 12-fold increased risk compared to simple increased nuchal translucency 3
• First-trimester anatomic survey can detect major malformations affecting brain, heart, abdominal wall, and limbs, though sensitivity is only 50% versus 75% at 18-22 weeks 2

Risk Stratification and Prognosis

The prognosis varies dramatically based on specific findings:

Favorable Prognosis Indicators

• Normal karyotype AND no structural anomalies AND no hydrops - these cases have the best outcomes 4, 5
• Late third-trimester diagnosis (after 30 weeks) with normal karyotype - generally good prognosis 6
• Approximately 20% of cystic hygromas regress or resolve during pregnancy 1

Poor Prognosis Indicators

• Hydrops fetalis - associated with either intrauterine fetal death or early perinatal death even with normal karyotype 4
• First or second-trimester diagnosis with abnormal karyotype - poor prognosis 6
• Septated cystic hygroma has 5-fold increased risk of aneuploidy, 12-fold increased risk of cardiac malformation, and 6-fold increased risk of perinatal death compared to simple increased nuchal translucency 3

Serial Surveillance Protocol

Timing and Frequency

• Serial ultrasound examinations every 2-4 weeks to monitor for:
  • Development of hydrops fetalis
  • Progression or resolution of the hygroma
  • Fetal growth
  • Development of additional structural anomalies
• More frequent surveillance in third trimester
• Include biophysical profiles and growth assessments 7

Specific Monitoring Parameters

• Assess for hydrops development (pleural effusions, ascites, skin edema, pericardial effusion)
• Monitor amniotic fluid volume - polyhydramnios is common (77% in some series) 8
• Evaluate fetal growth - growth restriction is a poor prognostic indicator
• Cardiac function assessment if structural heart disease present

Management Based on Findings

Euploid Fetus with Normal Anatomy and No Hydrops

• Continue serial surveillance as outlined above
• Offer second-trimester anatomic survey and fetal echocardiogram regardless of first-trimester findings, as risks remain elevated 2
• Plan delivery at tertiary center with pediatric surgery capability
• Counsel that 17% of first-trimester cystic hygromas with normal evaluation result in healthy infants with normal pediatric outcomes 3
• Important caveat: Even in favorable cases, 2-4% risk of unfavorable neurologic outcomes exists 5, 3

Aneuploid Fetus or Major Structural Anomalies

• Provide comprehensive genetic counseling
• Discuss options including continuation versus termination
• If continuation chosen, coordinate multidisciplinary delivery planning
• Most cases with aneuploidy or major structural defects result in intrauterine fetal death before 22 weeks 4

Development of Hydrops Fetalis

This is a critical turning point requiring immediate action:

• Without chromosomal or structural abnormalities: Consider candidates for intrauterine therapy 4

  • Sclerotherapy with OK-432 injection has been reported in select cases 4
  • However, most cases still result in intrauterine fetal death or early perinatal death from circulatory failure 4

• With chromosomal abnormalities or structural anomalies: Usually results in intrauterine fetal death before 22 weeks 4

• Maternal monitoring: Watch for mirror syndrome (maternal hydrops) which poses significant maternal risk 7

Delivery Planning

Timing

• Term delivery (37-39 weeks) for stable, euploid fetuses without complications
• Earlier delivery may be indicated if:
  • Progressive hydrops develops
  • Maternal mirror syndrome
  • Fetal compromise on surveillance testing

Location and Preparation

• Deliver at tertiary or quaternary center with:
  • Pediatric surgery expertise
  • Neonatal intensive care
  • Pediatric otolaryngology (for airway management)
  • ECMO capability if cardiac complications present 7

Mode of Delivery

• Cesarean delivery may be necessary for very large hygromas to avoid dystocia
• Prepare for potential airway obstruction at birth - have pediatric airway team present
• EXIT procedure (ex utero intrapartum treatment) may be considered for massive hygromas with anticipated airway compromise

Genetic Counseling for Cytogenetic Results

For Amniocentesis in Cases with IUFD

• Amniocentesis has 88.9% success rate for karyotyping 9
• Superior to postmortem chorionic villus sampling (69.2% success) 9
• Cystic hygroma paracentesis has only 20% success rate in IUFD cases 9

For Living Hydropic Fetuses with Oligohydramnios

• Cystic hygroma paracentesis is practical alternative when amniocentesis not feasible 9
• 100% success rate reported in living fetuses 9

Key Clinical Pitfalls to Avoid

1. Do not confuse with other entities: Cystic hygroma is distinct from simple increased nuchal translucency, lymphatic malformations without septations, and venous malformations 10, 11

2. Do not rely solely on cell-free DNA screening: While useful, it only detects common trisomies and misses conditions like Noonan syndrome and 22q11.2 deletion syndrome which can present with increased nuchal translucency 2

3. Do not assume good prognosis based on postnatal literature: Prenatally diagnosed cystic hygromas have significantly worse outcomes than those diagnosed postnatally 12

4. Do not skip fetal echocardiography: Even with normal karyotype, cardiac anomalies are common and significantly impact outcomes 2, 3

5. Do not underestimate risk in "isolated" findings: Even with normal karyotype and no obvious structural defects, 2-4% risk of adverse neurologic outcomes persists 5, 3